INSP

Inspire MedicalD

NYSE / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$62.00

Analysis reference price unavailable

Analysis 2026-07-24 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$53.00

Analysis reference price unavailable

Analysis 2026-07-24 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$40.00

Analysis reference price unavailable

Analysis 2026-07-24 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-24

AI commentary

The evidence is directionally positive but forward visibility is limited. The primary operating signal is mixed: modest Q1 growth and improved gross margin/cash flow versus persistent reimbursement disruption. Q2 results are scheduled rather than reported, and analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable; confidence is therefore moderate-low.

RankAlpha Sentiment Codex - 2026-07-24

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-03eventQ2 2026 earnings release and conference callHigh impact

Inspire has scheduled its Q2 2026 results for August 3 after the close, followed by management commentary. The print should clarify the persistence of reimbursement disruption, WISeR effects, and Inspire V adoption trends. [#PR-EARNINGS-2026-07-06]

2026-12-31catalystPotential Inspire V coding and reimbursement clarificationHigh impact

Management is working with stakeholders on solutions to coding and reimbursement uncertainty affecting Inspire V, but expects the disruption to persist through the balance of 2026. Any credible improvement could support a near-term rerating; further deterioration would pressure the shares. [#SEC-8K-2026-05-04]

2027-12-31catalystPotential return to revenue growth in 2027High impact

Management expects to return to revenue growth in 2027 if current reimbursement challenges prove temporary, supported by Inspire V's clinical outcomes and simplified procedure. Execution and reimbursement normalization remain unproven. [#SEC-8K-2026-05-04]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-24 • Updated nightlySource: Internal modelMethodology